Adenosylmethionine succinate, a new hepatobiliary drug from Zhenyuan, Zhejiang Province, has entered the final approval stage

This means that the drug has passed the technical review and production site inspection and entered the final approval stage Zhejiang Zhenyuan is expected to obtain the product production approval document in the first half of the year, when it will share the domestic market with Haizheng pharmaceutical, the first pharmaceutical imitator of the variety Zhejiang Zhenyuan related people have said that the product is an important specialty drug of the company, and will be promoted to the whole country through the combination of self-sale and agency after listing The price will be similar to that of Haizheng pharmaceutical industry, and there will be no vicious competition Zhejiang Zhenyuan also disclosed in its 2012 annual report that after the pre-approval of on-site verification and production approval documents, the product should be put into production as soon as possible, and the pre market preheating plan before listing should be intensified to shorten the cultivation coverage period of listing and strive for the market launch in that year, so as to produce benefits in that year It is reported that in the first half of 2013, the revenue of adenosylmethionine Succinate Tablets and injections of Haizheng Pharmaceutical Co., Ltd reached more than 100 million yuan, with good sales volume Data show that adenosylmethionine is a kind of physiologically active molecule commonly existing in human tissues and body fluids, which is mainly suitable for intrahepatic cholestasis and intrahepatic cholestasis in pregnancy before and after cirrhosis, and can make the abnormal liver function caused by various reasons turn to normal At present, there is only one Haizheng pharmaceutical company in China that produces the product; there are six domestic companies that apply for the production of the product, and Zhejiang Zhenyuan is ahead of schedule